SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation under Regulation 39(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 Is Taro buyback news triggering rally in Sun Pharma?
Analysts remain cautious, as the stock is volatile Sun Pharmaceutical Industries Ltd - 524715 - Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
The Exchange has received Disclosure under Regulation 31(1) and 31(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 on Novemeber 11, 2019 for Shanghvi Finance Pvt Ltd
NPPA exempts Sun Pharma's oncology injection from price control
The injection is used to treat various kinds of cancer.Sun Pharma got the approval for gemcitabine hydrochloride injection of 10mg/ml strength in ready to use infusion bags of 120ml, 140ml and 160 ml Here's why Sun Pharma is betting on Japan when peers are losing interest
Recently, Japan's sixth largest generic player Lupin said it felt that the annual price cuts made the market unattractive and it would continue to grow in single digits in value terms Sun Pharma Q2 results: Speciality business key to getting US business on track
Sun Pharma Q2 results: The drugmaker, which earns 37 per cent of its business from the US market, earned Rs 2,389.77 crore from the sale of formulations in the US in Q2FY20 against Rs 2397 crore in the corresponding quarter of the previous year Sun Pharmaceutical Industries Ltd - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to second quarter FY20 financials, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you, Sun Pharmaceutical Industries Ltd - 524715 - Outcome Of The Board Meeting Of The Company Held Today -Financial Results For The Half Year Ended 30.09.2019
Pursuant to Regulation 30 and 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors of the Company at its meeting held today i.e. Thursday,November 07, 2019, duly approved the Standalone and Consolidated Unaudited Financial Results for the quarter and six months ended September 30, 2019, which are enclosed herewith a1ongwith the Limited Review Report of the Statutory Auditors of the Company on Standalone and Consolidated Unaudited Financial Results. The meeting of the Board of Directors of the Company commenced at 11: 15 a.m. and concluded at 2:25 p.m. Sun Pharma, AstraZeneca shares rise up to 5% on agreement for sale of cancer drugs in China
AstraZeneca Pharma will sell Sun Pharma's cancer treatment drugs in China."The agreement will help to bring cost-effective and quality drugs to patients in China," the regulatory filing said. SUN PHARMACEUTICAL INDUSTRIES LTD. - 524715 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Please find enclosed herewith our Press Release relating to License Agreement with AstraZeneca for Novel Oncology products in China, which we shall be releasing after sending this letter to you. This is for your information and record. Thanking you,